North China Pharmaceutical Co Ltd (SHG:600812) — Market Cap & Net Worth
Market Cap & Net Worth: North China Pharmaceutical Co Ltd (600812)
North China Pharmaceutical Co Ltd (SHG:600812) has a market capitalization of $1.31 Billion (CN¥8.96 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #7992 globally and #2011 in its home market, demonstrating a -1.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying North China Pharmaceutical Co Ltd's stock price CN¥5.22 by its total outstanding shares 1715730370 (1.72 Billion). Analyse North China Pharmaceutical Co Ltd (600812) cash flow conversion to see how efficiently the company converts income to cash.
North China Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
North China Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.10 Billion to $1.31 Billion (-2.40% CAGR).
Index Memberships
North China Pharmaceutical Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$4.20 Trillion | 0.03% | #255 of 285 |
Weight: North China Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
North China Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how North China Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.13x
North China Pharmaceutical Co Ltd's market cap is 0.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
10.22x
North China Pharmaceutical Co Ltd's market cap is 10.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.10 Billion | $7.90 Billion | $62.85 Million | 0.27x | 33.38x |
| 2016 | $1.53 Billion | $8.08 Billion | $54.42 Million | 0.19x | 28.13x |
| 2017 | $1.21 Billion | $7.71 Billion | $18.76 Million | 0.16x | 64.60x |
| 2018 | $983.35 Million | $9.21 Billion | $150.65 Million | 0.11x | 6.53x |
| 2019 | $2.44 Billion | $11.46 Billion | $172.15 Million | 0.21x | 14.15x |
| 2020 | $2.55 Billion | $11.49 Billion | $97.32 Million | 0.22x | 26.23x |
| 2021 | $2.96 Billion | $10.38 Billion | $18.73 Million | 0.29x | 158.31x |
| 2022 | $1.61 Billion | $10.50 Billion | -$689.23 Million | 0.15x | N/A |
| 2023 | $1.43 Billion | $10.12 Billion | $4.89 Million | 0.14x | 292.63x |
| 2024 | $1.30 Billion | $9.87 Billion | $126.99 Million | 0.13x | 10.22x |
Competitor Companies of 600812 by Market Capitalization
Companies near North China Pharmaceutical Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to North China Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #501 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #530 globally with a market cap of $50.06 Billion USD ( CN¥342.11 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #541 globally with a market cap of $49.01 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #574 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #501 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.06 Billion | CN¥53.63 |
| #541 | Zoetis Inc | NYSE:ZTS | $49.01 Billion | $111.22 |
| #574 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $43.83 |
North China Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, North China Pharmaceutical Co Ltd's market cap moved from $2.10 Billion to $ 1.31 Billion, with a yearly change of -2.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.31 Billion | -5.61% |
| 2025 | CN¥1.39 Billion | +6.96% |
| 2024 | CN¥1.30 Billion | -9.30% |
| 2023 | CN¥1.43 Billion | -10.94% |
| 2022 | CN¥1.61 Billion | -45.80% |
| 2021 | CN¥2.96 Billion | +16.16% |
| 2020 | CN¥2.55 Billion | +4.77% |
| 2019 | CN¥2.44 Billion | +147.74% |
| 2018 | CN¥983.35 Million | -18.85% |
| 2017 | CN¥1.21 Billion | -20.82% |
| 2016 | CN¥1.53 Billion | -27.06% |
| 2015 | CN¥2.10 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of North China Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.31 Billion USD |
| MoneyControl | $1.31 Billion USD |
| MarketWatch | $1.31 Billion USD |
| marketcap.company | $1.31 Billion USD |
| Reuters | $1.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About North China Pharmaceutical Co Ltd
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China and internationally. The company primarily offers anti-infective drugs, biotechnology drugs, cardiovascular cerebrovascular, immunomodulators, and vitamins and health products. It also provides chemical pharmaceuticals; and biological, agricultural, and veterin… Read more